Biosimilars Conference

Forecasting future regulatory, commercial & legal challenges to advance biosimilars uptake


London, United Kingdom

We are delighted to announce the 10th annual Biosimilars and Biologics conference taking place on 25th and 26th of September 2019 in London, UK. We will be collating our audience and holding our first international conference in London.

The biosimilars market is forecasted to reach USD$23.6B by 2023 at a compound annual growth rate (CAGR) of 31.70%. Factors driving the increase of this market include growing demand for biosimilar drugs due to their cost-effectiveness, growing incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

With the expiry dates of major patents fast approaching, the emerging gap in the market for biosimilars is now a major attraction for  manufacturers. As the availability of biosimilars could potentially reduce direct spending by USD$54B by 2026, the question is what can current biosimilar producing companies do to join this market to benefit the patients, physicians and investors?

Benefits of Attending

  • HEAR about the current updates in patent laws provided by legal experts
  • DISCUSS the strategies being implemented to enhance the medical communication between stakeholders, physicians and patients
  • EXPLORE the landscape of biosimilar commercialization in various international markets

Who should attend

Presidents, Vice Presidents, Managing Directors, Directors, Associate Directors, Chiefs, Heads, Principals, Managers and Analysts of:
  • Biosimilar Development
  • Product Development
  • Commercialization
  • Market Access
  • Medical Affairs
  • Intellectual Property
  • Bioloigcs
  • Biopharmaceuticals
  • Research and Development
  • Generics
  • Biobetters
  • Business Development
  • Strategic Marketing
  • Drug Development
  • Clinical Trials
  • Immunogenecity Studies
Global Presence:
Attendees from all over the world attend our events. Gain hands on insight from representatives from UK, Europe and USA.

Plus Two Interactive Half-Day Pre- Conference Workshops | Tuesday 24th September 2019

Workshop B: Interchangeability in the USA: The US-FDA Regulatory Guidance
Workshop Leader: Michel Mikhail, International Expert Regulatory Affairs, Global Expert Biosimilars
8.30 - 12.30

Workshop B: Advancing biosimilars development and uptake in MENA and GCC regions
Workshop Leader: Rodeina Challand, General Manager,Challand Biosimilar Consulting
13.30 - 17.30

Speakers

  • Anne Cook, Biologicals Quality Assessor, MHRA
  • Aurelio Arias, Senior Consultant, Thought Leadership, IQVIA
  • Bert E. Thomas IV, Senior Vice President, Business Development, Bio-Thera Solutions, Ltd
  • Christian Agboton, Senior Global Brand Medical Director, Takeda Pharmaceuticals International GmbH
  • Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP
  • Corinna Sonderegger, Sandoz Biopharmaceuticals, Sandoz
  • Dan Cohen, Regional Senior Director, Biosimilars UK, Ireland and Netherlands, Biogen Idec Limited
  • Gregory Bacon, Partner, Bristows LLP
  • Jaap Wieling, Chief Development Officer, BiosanaPharma BV
  • Liz Pollitt, Director, BioPharma CMC Regulatory Consultancy Services Ltd
  • Louis Boon, CSO Bioceros BV, Bioceros BV
  • Meenu Wadhwa, Section Leader Biotherapeutics Group, National Institute for Biological Standards and Control
  • Michel Mikhail, International Expert in Regulatory Affairs, International Expert in Biosimilars, Independant Consultant
  • Rodeina Challand, Executive Director, Project Management, Worldwide Clinical Trials, Challand Biosimilar Consulting
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Stephen Murby, Board Member, Alliance for Safe Biologic Medicines (ASBM)

Venue

Copthorne Tara Hotel
Scarsdale Place, Kensington
London, United Kingdom